Business Wire

Mobile Industry Accelerating Delivery of Sustainable Development Goals, According to Latest GSMA Report

Del

The global mobile industry is demonstrating significant and measurable impact in contributing to the UN’s Sustainable Development Goals (SDGs) and is strengthening its commitment to improving lives around the world, according to a new GSMA study. The 2018 edition of the GSMA’s annual ‘Mobile Industry Impact’ report, published at the UN General Assembly this week, found that the industry has continued to increase its contribution against all 17 Goals since mobile become the first sector in the world to commit to delivery of the SDGs in 2016. This growing impact reflects mobile’s unprecedented global scale, which provides a platform to connect unconnected communities, reduce poverty, improve access to healthcare and education, and drive sustainable economic growth.

“More than two-thirds of the people on the planet are now connected to a mobile network and, for many, mobile is the primary – sometimes only – channel for accessing the internet and life-enhancing services,” commented Mats Granryd, Director General of the GSMA. “Today’s report reiterates how the mobile industry is playing a central role in accelerating delivery of the SDGs and leveraging the power of mobile networks and services to transform lives around the world.”

Measuring Mobile’s Impact and Turning Commitment into Action

The Mobile Industry Impact study uses a proprietary methodology to assign an ‘impact score’ to measure the industry’s contribution to each of the 17 Goals. In every case, the scores have improved year-on-year since 2015 as mobile operators worldwide increasingly embed the SDGs into their core values, strategies, policies and services, transforming the industry’s commitment to the SDGs into real-world initiatives that are delivering measurable results.

According to the report, the mobile industry’s greatest impact is currently on SDG 9 (Industry, Innovation and Infrastructure), a result of near-universal mobile network coverage that is driving new business models in areas such as the sharing economy, mobile savings and credit, and pay-as-you-go solar models to access clean energy. However, since 2015, the industry has increased its impact most substantially against SDG 13 (Climate Action), SDG 11 (Sustainable Cities and Communities), and SDG 3 (Good Health and Well-Being). A key driver of the higher impact on these three Goals relates to the use of mobile phones and networks to provide essential humanitarian assistance during epidemics and natural or climate-related disasters.

The study highlights a number of examples of where exceptional progress has been made over the last three years:

  • More than 5 billion people are today connected to a mobile network, equivalent to roughly two-thirds (66 per cent) of the world’s population, up from 4.6 million at the end of 2015, which means that the industry has added more than 400 million unique mobile subscribers over this period.
  • Almost 600 million additional people, the vast majority from low- and middle-income countries, have begun using mobile internet services since 2015, bringing the total to 3.3 billion at the end of 2017. By the end of this decade, it is forecast that half of the world’s population will accessing the internet via their phones, up from 36 per cent in 2015.
  • More than 250 million people have started to use mobile money since 2015, enabling access to a range of financial services to those who would otherwise be excluded from the banking system and bringing the total number of mobile money accounts to nearly 700 million at the end of 2017.
  • There are now more than 750,000 education-related apps available on smartphones, up 62 per cent from 2015, resulting in 1.2 billion people using mobile to improve their education or the education of their children, and also bridging the gender gap in access to education.
  • In 2017, signatories to the GSMA Humanitarian Connectivity Charter provided essential humanitarian assistance to more than 30 million people during epidemics and natural disasters, for example, in the aftermaths of Hurricane Maria in Puerto Rico and the monsoon floods in Nepal.
  • Since 2015, more than 1 million households have installed solar home systems using a mobile-enabled pay-as you-go model, bringing them clean and affordable access to electricity.
  • Five million more people have begun used mobile-enabled agricultural services supported by the GSMA’s mNutrition Initiative since 2015, giving farmers access to vital information that allows them to improve agricultural productivity and incomes.

“The 2030 deadline to meet the SDGs may seem a distant horizon today, but it is critical that all stakeholders – governments, the mobile industry and other sectors – take concerted and urgent action now to further accelerate progress,” added Granryd. “We must continue to develop initiatives that connect the unconnected and drive mobile internet adoption, while scaling up the mobile-enabled products and services that are providing real-world solutions to developmental challenges.”

The 2018 Mobile Industry Impact Report was authored by GSMA Intelligence, the research arm of the GSMA. The report provides summaries on mobile’s impact on all 17 SDGs, alongside in-depth analysis on five selected SDGs that showcase innovative case studies of operator initiatives supporting the Goals.

Click here to download the report

As part of its commitment to the SDGs, the GSMA is working closely with the industry, policymakers, and the international development community to help connect the unconnected and to identify new opportunities to leverage and scale mobile-enabled solutions that improve people’s quality of life. This work is being done through several ongoing GSMA programmes and initiatives, including Mobile for Development, which identifies opportunities and delivers innovations with socioeconomic impact in financial services, health, agriculture, digital identity, energy, water, sanitation, disaster resilience and gender equality; Big Data for Social Good; and We Care.

-ENDS-

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators with over 350 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

Contact information

For the GSMA
Beau Bass
+44 79 7662 4962
beau.bass@webershandwick.com
or
Amelise Lane
+1 212 546 7830
alane@webershandwick.com
or
GSMA Press Office
pressoffice@gsma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an